ArticleClinical, cosmetic and investigational dermatology2026
A Retrospective Analysis of Radiofrequency Microneedling for Melasma Management in the Japanese Population.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Study.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Melasma is a chronic pigmentary disorder with multifactorial pathogenesis and significant psychosocial impact. Although radiofrequency microneedling has emerged as a dermal-targeting adjunctive therapy, real-world evidence regarding its clinical effects and safety is limited. Objective: To evaluate the real-world clinical response and safety of POTENZA Methods: A retrospective observational before-and-after study was conducted at a private dermatology center in Japan. Adult patients with clinically diagnosed melasma who underwent POTENZA Results: A total of 29 female patients (mean age, 45.2 ± 7.9 years) were included in the study. The median baseline mMASI score was 6 (IQR 4-12) and remained 6 (IQR 4-8) after treatment, with no statistically significant difference between the time points (p = 0.16). Overall, 26 patients (89.7%) demonstrated stable or improved mMASI scores post procedure. Percentage-based analyses showed substantial interindividual variability: 27.6% of patients achieved≥25% and ≥30% reductions in mMASI, and 10.3% achieved≥50% reduction. Patient satisfaction was reported in 62.1% of the cases. All patients experienced mild, transient erythema that resolved without sequelae, and no serious adverse events were observed. Conclusion: In this real-world study involving Japanese patients, POTENZA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.